OOIR: Observatory of International Research

Papers

(The H4-Index of Journal for Immunotherapy of Cancer is 70. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future	301
Vaccination with early ferroptotic cancer cells induces efficient antitumor immunity	262
Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometri	166
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events	151
Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose?	146
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice	144
Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer	142
Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies	132
HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy	132
Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer	128
STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation	127
Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers	126
Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer	121
Phagocytic function of tumor-associated macrophages as a key determinant of tumor progression control: a review	121
KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma	119
Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer	118
Acute kidney injury in patients treated with immune checkpoint inhibitors	118
CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer	116
Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead	112
Intratumoral CXCL13⁺CD8⁺T cell infiltration determines poor clinical outcomes and immunoevasive contexture in patients with clear cell renal cell carcinoma	111
Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma	110
Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma	109
Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer	109
Therapeutic depletion of CCR8⁺tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy	106
Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial	101

Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial	100
Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors	99
Non-invasive measurement of PD-L1 status and prediction of immunotherapy response using deep learning of PET/CT images	96
Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma	96
Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial	93
Mitochondrial Lon-induced mtDNA leakage contributes to PD-L1–mediated immunoescape via STING-IFN signaling and extracellular vesicles	92
Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy	91
Deregulation of HLA-I in cancer and its central importance for immunotherapy	91
Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma	91
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies	89
Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies	87
Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial	87
Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers	87
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemothera	85
Rethinking immune checkpoint blockade: ‘Beyond the T cell’	85
Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1	84
TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy	84
A signature for pan-cancer prognosis based on neutrophil extracellular traps	84
Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma	84
Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy.	81
S100A4 enhances protumor macrophage polarization by control of PPAR-γ-dependent induction of fatty acid oxidation	80
COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies	80
Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma	80
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targ	78
Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors	78
Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer	77
Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC)	76
Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages	76
TGFβ drives NK cell metabolic dysfunction in human metastatic breast cancer	76
Influence of injection technique, drug formulation and tumor microenvironment on intratumoral immunotherapy delivery and efficacy	76
Severity of COVID-19 in patients with lung cancer: evidence and challenges	76
STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment	76
Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors	75
Tumors establish resistance to immunotherapy by regulating T_regrecruitment via CCR4	75
Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade	75
Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma	75
Follicular helper-T cells restore CD8⁺-dependent antitumor immunity and anti-PD-L1/PD-1 efficacy	74
Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer	74
Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor–treated unresectable hepatocellular carcinoma	73
Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer	73
Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinoma	72
Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma	72
Tumor-infiltrating plasmacytoid dendritic cells are associated with survival in human colon cancer	72
Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck	71
Considerations for treatment duration in responders to immune checkpoint inhibitors	71
Combination of gemcitabine and anti-PD-1 antibody enhances the anticancer effect of M1 macrophages and the Th1 response in a murine model of pancreatic cancer liver metastasis	70